NO883963L - Modifiserte plasminogenaktivatorer. - Google Patents

Modifiserte plasminogenaktivatorer.

Info

Publication number: NO883963L
Authority: NO; Norway
Prior art keywords: dna; upa; region; fragment; amino acid
Prior art date: 1987-09-07

Application number

NO88883963A

Other languages

English (en)

Norwegian (no)

Other versions

NO883963D0 (no

Inventor

Giovanni Cassani

Marialuisa Nolli

Francesco Blasi

Federico Maria Robbiati

Original Assignee

Lepetit Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-07

Filing date

1988-09-06

Publication date

1989-03-08

1988-09-06 Application filed by Lepetit Spa filed Critical Lepetit Spa

1988-09-06 Publication of NO883963D0 publication Critical patent/NO883963D0/no

1989-03-08 Publication of NO883963L publication Critical patent/NO883963L/no

Links

102000001938 Plasminogen Activators Human genes 0.000 title claims description 11
108010001014 Plasminogen Activators Proteins 0.000 title claims description 11
229940127126 plasminogen activator Drugs 0.000 title claims description 11
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 236
108020004414 DNA Proteins 0.000 claims description 227
102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 190
210000004027 cell Anatomy 0.000 claims description 108
238000000034 method Methods 0.000 claims description 84
150000001413 amino acids Chemical class 0.000 claims description 43
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 33
239000013604 expression vector Substances 0.000 claims description 33
108091026890 Coding region Proteins 0.000 claims description 31
230000037430 deletion Effects 0.000 claims description 25
238000012217 deletion Methods 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 17
230000037431 insertion Effects 0.000 claims description 15
238000003780 insertion Methods 0.000 claims description 15
125000003275 alpha amino acid group Chemical group 0.000 claims description 14
210000004102 animal cell Anatomy 0.000 claims description 8
230000035772 mutation Effects 0.000 claims description 7
230000010005 growth-factor like effect Effects 0.000 claims description 5
230000008569 process Effects 0.000 claims description 4
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
210000002700 urine Anatomy 0.000 claims description 4
238000012258 culturing Methods 0.000 claims 1
239000012634 fragment Substances 0.000 description 141
239000013612 plasmid Substances 0.000 description 127
239000000872 buffer Substances 0.000 description 68
108090000623 proteins and genes Proteins 0.000 description 68
239000013598 vector Substances 0.000 description 68
102000004169 proteins and genes Human genes 0.000 description 46
235000018102 proteins Nutrition 0.000 description 45
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
238000003776 cleavage reaction Methods 0.000 description 43
230000007017 scission Effects 0.000 description 43
108090000790 Enzymes Proteins 0.000 description 42
102000004190 Enzymes Human genes 0.000 description 42
229940088598 enzyme Drugs 0.000 description 42
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
239000000203 mixture Substances 0.000 description 39
229960005356 urokinase Drugs 0.000 description 36
235000001014 amino acid Nutrition 0.000 description 35
238000002360 preparation method Methods 0.000 description 33
108700026244 Open Reading Frames Proteins 0.000 description 31
238000003556 assay Methods 0.000 description 31
230000027455 binding Effects 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 30
238000010276 construction Methods 0.000 description 30
229960000723 ampicillin Drugs 0.000 description 27
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 27
238000004458 analytical method Methods 0.000 description 26
108020003175 receptors Proteins 0.000 description 24
102000005962 receptors Human genes 0.000 description 24
102000012410 DNA Ligases Human genes 0.000 description 23
108010061982 DNA Ligases Proteins 0.000 description 23
241000588724 Escherichia coli Species 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
108091003079 Bovine Serum Albumin Proteins 0.000 description 22
239000011543 agarose gel Substances 0.000 description 22
239000000499 gel Substances 0.000 description 22
230000004048 modification Effects 0.000 description 22
238000012986 modification Methods 0.000 description 22
239000000243 solution Substances 0.000 description 22
108020004999 messenger RNA Proteins 0.000 description 21
239000011780 sodium chloride Substances 0.000 description 21
239000002609 medium Substances 0.000 description 20
101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 19
238000000746 purification Methods 0.000 description 19
239000006228 supernatant Substances 0.000 description 18
108700024394 Exon Proteins 0.000 description 17
238000004519 manufacturing process Methods 0.000 description 17
238000001556 precipitation Methods 0.000 description 17
238000002474 experimental method Methods 0.000 description 16
229920000936 Agarose Polymers 0.000 description 15
230000014509 gene expression Effects 0.000 description 15
238000011049 filling Methods 0.000 description 14
239000000523 sample Substances 0.000 description 14
238000001890 transfection Methods 0.000 description 14
239000002299 complementary DNA Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 13
229960005542 ethidium bromide Drugs 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
102000003960 Ligases Human genes 0.000 description 12
108090000364 Ligases Proteins 0.000 description 12
239000012894 fetal calf serum Substances 0.000 description 12
230000002779 inactivation Effects 0.000 description 11
238000011534 incubation Methods 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
229940098773 bovine serum albumin Drugs 0.000 description 10
238000001962 electrophoresis Methods 0.000 description 10
238000000605 extraction Methods 0.000 description 10
239000012071 phase Substances 0.000 description 10
239000000047 product Substances 0.000 description 10
230000009466 transformation Effects 0.000 description 10
108020004705 Codon Proteins 0.000 description 9
108010088842 Fibrinolysin Proteins 0.000 description 9
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
230000029087 digestion Effects 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
230000002255 enzymatic effect Effects 0.000 description 9
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 9
210000004962 mammalian cell Anatomy 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
125000003729 nucleotide group Chemical group 0.000 description 9
239000001301 oxygen Substances 0.000 description 9
229910052760 oxygen Inorganic materials 0.000 description 9
230000036961 partial effect Effects 0.000 description 9
229940012957 plasmin Drugs 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
102000004594 DNA Polymerase I Human genes 0.000 description 8
108010017826 DNA Polymerase I Proteins 0.000 description 8
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
102000009123 Fibrin Human genes 0.000 description 8
108010073385 Fibrin Proteins 0.000 description 8
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 8
108700039691 Genetic Promoter Regions Proteins 0.000 description 8
108091092195 Intron Proteins 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
101150055766 cat gene Proteins 0.000 description 8
229950003499 fibrin Drugs 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
238000012216 screening Methods 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
239000000126 substance Substances 0.000 description 8
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
229920002684 Sepharose Polymers 0.000 description 7
239000004098 Tetracycline Substances 0.000 description 7
238000010828 elution Methods 0.000 description 7
230000010076 replication Effects 0.000 description 7
229960002180 tetracycline Drugs 0.000 description 7
229930101283 tetracycline Natural products 0.000 description 7
235000019364 tetracycline Nutrition 0.000 description 7
150000003522 tetracyclines Chemical class 0.000 description 7
238000011144 upstream manufacturing Methods 0.000 description 7
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
229920001817 Agar Polymers 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000276498 Pollachius virens Species 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
238000001042 affinity chromatography Methods 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
239000001506 calcium phosphate Substances 0.000 description 6
229910000389 calcium phosphate Inorganic materials 0.000 description 6
235000011010 calcium phosphates Nutrition 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
238000004255 ion exchange chromatography Methods 0.000 description 6
239000006166 lysate Substances 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
241001131785 Escherichia coli HB101 Species 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 5
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000008272 agar Substances 0.000 description 5
239000005018 casein Substances 0.000 description 5
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
235000021240 caseins Nutrition 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
230000003480 fibrinolytic effect Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
238000010353 genetic engineering Methods 0.000 description 5
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000003119 immunoblot Methods 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
230000008488 polyadenylation Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
238000004366 reverse phase liquid chromatography Methods 0.000 description 5
239000012064 sodium phosphate buffer Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 5
230000001131 transforming effect Effects 0.000 description 5
238000005406 washing Methods 0.000 description 5
108010039627 Aprotinin Proteins 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
241001646716 Escherichia coli K-12 Species 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 4
102000013566 Plasminogen Human genes 0.000 description 4
108010051456 Plasminogen Proteins 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
229960004405 aprotinin Drugs 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
239000003527 fibrinolytic agent Substances 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000013641 positive control Substances 0.000 description 4
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
230000014616 translation Effects 0.000 description 4
238000013519 translation Methods 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102000012545 EGF-like domains Human genes 0.000 description 3
108050002150 EGF-like domains Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
108010051815 Glutamyl endopeptidase Proteins 0.000 description 3
108091036060 Linker DNA Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000008118 PEG 6000 Substances 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000009835 boiling Methods 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
239000012847 fine chemical Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000005304 joining Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
150000007523 nucleic acids Chemical group 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
235000012434 pretzels Nutrition 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000001525 receptor binding assay Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000007974 sodium acetate buffer Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
108700026226 TATA Box Proteins 0.000 description 2
239000008051 TBE buffer Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003024 amidolytic effect Effects 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000009144 enzymatic modification Effects 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
239000006167 equilibration buffer Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000003317 immunochromatography Methods 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000010410 layer Substances 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
-1 lysine or arginine Chemical class 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002760 pro-activator Effects 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000012429 reaction media Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
108010073863 saruplase Proteins 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 1
101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000008836 DNA modification Effects 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
241000388186 Deltapapillomavirus 4 Species 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000005630 Diquat Substances 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 1
101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 1
241001452028 Escherichia coli DH1 Species 0.000 description 1
101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
101710103262 Glandular kallikrein Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101100176745 Mus musculus Gsc2 gene Proteins 0.000 description 1
101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108090000113 Plasma Kallikrein Proteins 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 1
241000382353 Pupa Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
101100121694 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GFD2 gene Proteins 0.000 description 1
241000702208 Shigella phage SfX Species 0.000 description 1
101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 1
101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 1
101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000057032 Tissue Kallikreins Human genes 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108091060592 XDNA Proteins 0.000 description 1
101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 1
101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 1
101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000008901 benefit Effects 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000010200 folin Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000007169 ligase reaction Methods 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000010187 selection method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000012799 strong cation exchange Methods 0.000 description 1
239000013595 supernatant sample Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

NO88883963A 1987-09-07 1988-09-06 Modifiserte plasminogenaktivatorer. NO883963L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB878721023A GB8721023D0 (en)	1987-09-07	1987-09-07	Modified plasminogen activators

Publications (2)

Publication Number	Publication Date
NO883963D0 NO883963D0 (no)	1988-09-06
NO883963L true NO883963L (no)	1989-03-08

Family

ID=10623401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO88883963A NO883963L (no)	1987-09-07	1988-09-06	Modifiserte plasminogenaktivatorer.

Country Status (14)

Country	Link
EP (1)	EP0308716A3 (xx)
JP (1)	JPH01117785A (xx)
KR (1)	KR890005267A (xx)
CN (1)	CN1033070A (xx)
AU (1)	AU2196688A (xx)
DK (1)	DK491988A (xx)
FI (1)	FI883943A (xx)
GB (1)	GB8721023D0 (xx)
HU (1)	HUT47975A (xx)
IL (1)	IL87638A (xx)
NO (1)	NO883963L (xx)
NZ (1)	NZ226050A (xx)
PT (1)	PT88436B (xx)
ZA (1)	ZA886401B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5098840A (en) *	1986-07-03	1992-03-24	The Green Cross Corporation	Human prourokinase mutants
AU5515790A (en) *	1989-05-18	1990-11-22	Green Cross Corporation, The	Human prourokinase variants, methods of producing same, dna sequences, plasmids and hosts therefor
CA2025181A1 (en) *	1989-10-12	1991-04-13	William G. Weisburg	Nucleic acid probes and methods for detecting fungi
JPH0595786A (ja) *	1991-10-07	1993-04-20	Green Cross Corp:The	変異ヒトプロウロキナーゼ
US6120765A (en) *	1993-04-02	2000-09-19	Shiseido Co. Ltd.	Urokinase plasminogen activator fragments
CA2605127C (en)	2005-04-19	2011-08-09	Archer-Daniels-Midland Company	Soluble non-caloric fiber composition and process of preparing the same
TWI369402B (en)	2006-07-05	2012-08-01	Catalyst Biosciences Inc	Protease screening methods and proteases identified thereby
JP2010512324A (ja)	2006-12-08	2010-04-22	アッテヌオンエルエルシー	ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8801374A1 (es) *	1985-04-04	1988-01-01	Beecham Group Plc	Un procedimiento para preparar un activante de plasminogeno.
JPH0761266B2 (ja) *	1986-07-03	1995-07-05	株式会社ミドリ十字	変異ヒトプロウロキナ−ゼ
EP0266032A1 (en) *	1986-08-29	1988-05-04	Beecham Group Plc	Modified fibrinolytic enzyme
IE880255L (en) *	1987-01-30	1988-07-30	American Home Prod	Des-epidermal growth factor activators.

1987
- 1987-09-07 GB GB878721023A patent/GB8721023D0/en active Pending
1988
- 1988-08-26 FI FI883943A patent/FI883943A/fi not_active Application Discontinuation
- 1988-08-29 ZA ZA886401A patent/ZA886401B/xx unknown
- 1988-08-31 IL IL87638A patent/IL87638A/xx unknown
- 1988-09-05 NZ NZ226050A patent/NZ226050A/xx unknown
- 1988-09-05 DK DK491988A patent/DK491988A/da not_active Application Discontinuation
- 1988-09-06 NO NO88883963A patent/NO883963L/no unknown
- 1988-09-06 EP EP88114516A patent/EP0308716A3/en not_active Withdrawn
- 1988-09-06 HU HU884603A patent/HUT47975A/hu unknown
- 1988-09-06 PT PT88436A patent/PT88436B/pt not_active IP Right Cessation
- 1988-09-07 CN CN88106601A patent/CN1033070A/zh active Pending
- 1988-09-07 KR KR1019880011529A patent/KR890005267A/ko not_active Application Discontinuation
- 1988-09-07 AU AU21966/88A patent/AU2196688A/en not_active Abandoned
- 1988-09-07 JP JP63224371A patent/JPH01117785A/ja active Pending

Also Published As

Publication number	Publication date
FI883943A0 (fi)	1988-08-26
DK491988A (da)	1989-03-08
NZ226050A (en)	1991-06-25
IL87638A (en)	1993-04-04
JPH01117785A (ja)	1989-05-10
EP0308716A2 (en)	1989-03-29
NO883963D0 (no)	1988-09-06
KR890005267A (ko)	1989-05-13
PT88436A (pt)	1989-07-31
AU2196688A (en)	1989-06-08
CN1033070A (zh)	1989-05-24
FI883943A (fi)	1989-03-08
IL87638A0 (en)	1989-01-31
PT88436B (pt)	1992-11-30
GB8721023D0 (en)	1987-10-14
ZA886401B (en)	1989-07-26
DK491988D0 (da)	1988-09-05
EP0308716A3 (en)	1989-06-14
HUT47975A (en)	1989-04-28

Publication	Publication Date	Title
KR970002166B1 (ko)	1997-02-24	단백질 c를 암호화하는 dna 서열, 이를 함유하는 재조합 벡터, 재조합 벡터를 함유하는 포유동물 세포 및 단백질 c를 제조하는 방법
CA2024607C (en)	1999-11-30	Recombinant dna method and host cells
BG60253B2 (bg)	1994-03-24	Човешки тъканен плазминогенен активатор
JP2605155B2 (ja)	1997-04-30	新規なヒト組織プラスミノーゲンアクチベーター変異体および方法
Fen et al.	1993	Structural organization and chromosomal assignment of the gene encoding the human heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor
US5869314A (en)	1999-02-09	Tissue plasminogen activators and derivatives thereof as produced by recombinant means
JP2641875B2 (ja)	1997-08-20	ハイブリッドタンパク質
NO883963L (no)	1989-03-08	Modifiserte plasminogenaktivatorer.
JP3043403B2 (ja)	2000-05-22	ヒトプラスミノーゲン変異体を発現させる方法及びその原料
JPH0761262B2 (ja)	1995-07-05	遺伝子操作による因子ＸＩＩＩａの製造法
EP0195592A2 (en)	1986-09-24	Factor IX protein
US5185259A (en)	1993-02-09	Truncated human tissue plasminogen activator
AU644352B2 (en)	1993-12-09	Expression induction method employing mutant dhfr gene
REDDY et al.	1987	Expression of human uterine tissue-type plasminogen activator in mouse cells using BPV vectors
EP0299706A2 (en)	1989-01-18	Nonglycosylated plasminogen activator and method of preparation
PT87230B (pt)	1992-08-31	Processo para a producao de proteinas
NO882791L (no)	1989-02-13	Fremgangsmaate for fremstilling av enkeltkjede urokinase.
KR20080036561A (ko)	2008-04-28	조직 플라스미노겐 활성제의 재조합 형태의 제조 방법
Weidle et al.	1987	Establishment of a temperature-inducible cell line for human plasminogen activator (tissue-type) by transfection of monkey cells with expression constructs
JPH04218383A (ja)	1992-08-07	プラスミド、形質転換された動物細胞及び異種蛋白質の製造方法
JPH022338A (ja)	1990-01-08	真核細肪中での同時発現
NO882051L (no)	1988-05-11	Mrna-stabilisering i dyreceller.
SI8810195A (sl)	1996-08-31	Hibridni proteini